Home/Pipeline/MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax + MP0533 with Obinutuzumab pretreatment + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients

ProductsMP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax + MP0533 with Obinutuzumab pretreatment + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients

MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax + MP0533 with Obinutuzumab pretreatment + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Leukemia

Conditions

Leukemia, Myeloid, Acute, Newly Diagnosed

Trial Timeline

Dec 29, 2022 → Dec 1, 2029

NCT ID

NCT05673057

About MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax + MP0533 with Obinutuzumab pretreatment + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients

MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A + MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax + MP0533 with Obinutuzumab pretreatment + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML + MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients is a phase 1/2 stage product being developed by Molecular Partners for Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05673057. Target conditions include Leukemia, Myeloid, Acute.

What happened to similar drugs?

20 of 20 similar drugs in Leukemia were approved

Approved (20) Terminated (1) Active (0)

✅micafungin + posaconazoleAstellas PharmaApproved

✅PirtobrutinibEli LillyApproved

✅Pirtobrutinib + IdelalisibEli LillyApproved

✅Ibrutinib 420 mg + Ibrutinib 560 mgJohnson & JohnsonApproved

✅Venetoclax + AzacitidineAbbVieApproved

✅Venetoclax + Azacitidine + AzacitidineAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05673057	Phase 1/2	Recruiting	Dec 29, 2022	Dec 1, 2029	Leukemia

Competing Products

20 competing products in Leukemia

See all competitors

Product	Company	Stage	Hype Score
AFM28	Affimed	Phase 1	11
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen	CSPC Pharmaceutical Group Limited	Phase 2	42
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells	CSPC Pharmaceutical Group Limited	Phase 2	39
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
PRGN-3006 T Cells	Precigen	Phase 1	27
Bisantrene	Race Oncology	Phase 2	29
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridine	Race Oncology	Phase 1	15
Bisantrene + Fludarabine + Clofarabine	Race Oncology	Phase 2	25
ZN-d5 ZN-c3 + ZN-c3	Zentalis Pharmaceuticals	Phase 1/2	14
ZN-d5	Zentalis Pharmaceuticals	Phase 1	19
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
VIP943 (QW) + VIP943 (BIW)	Vincerx Pharma	Phase 1	26
Pirtobrutinib + Ibrutinib	Eli Lilly	Phase 3	47
LY2523355	Eli Lilly	Phase 1	21
Tomivosertib	eFFECTOR Therapeutics	Phase 1	23
gemtuzumab ozogamycin	Chugai Pharmaceutical	Phase 3	40